【佳学基因检测】医师资格考试中，如何准备关于ADRA1B的相关内容？

基因检测的序列名称：

ADRA1B

人体基因序列变化与疾病表征数据库中的基因代码：

147

人体基因序列数据库中国际交流名称全称

adrenoceptor alpha 1B

中国数据库中基因全称：

肾上腺素受体1B

基因检测报告英文版基因简介

Alpha-1-adrenergic receptors (alpha-1-ARs) are members of the G protein-coupled receptor superfamily. They activate mitogenic responses and regulate growth and proliferation of many cells. There are 3 alpha-1-AR subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. This gene encodes alpha-1B-adrenergic receptor, which induces neoplastic transformation when transfected into NIH 3T3 fibroblasts and other cell lines. Thus, this normal cellular gene is identified as a protooncogene. This gene comprises 2 exons and a single large intron of at least 20 kb that interrupts the coding region. [provided by RefSeq, Jul 2008]

基因突变所影响的基因信息

Alpha-1-肾上腺素受体（alpha-1-ARs）是G蛋白偶联受体超家族的成员。它们激活有丝分裂反应并调节许多细胞的生长和增殖。存在3种alpha-1-AR亚型：alpha-1A，-1B和-1D，它们均通过G蛋白的Gq / 11家族发出信号，不同的亚型显示出不同的激活模式。该基因编码α-1B-肾上腺素能受体，当转染到NIH 3T3成纤维细胞和其他细胞系中时会诱导肿瘤转化。因此，该正常细胞基因被鉴定为原癌基因。该基因包含2个外显子和一个至少20 kb的大内含子，可中断编码区。[由RefSeq提供，200ು୔

国际国内该碱基因序列的其他英语文字母简称：

ADRA1, ALPHA1BAR

基因解码对该基因序列在细胞核中的染色体所给予的编号：

该基因序列位于人类第5号染色体上。

基因解码对基因序列的正确定位

该基因序列在GRCh37版本中的起始位置坐标为：159343740；结束位置坐标为：159400017。该基因序列在GRCh38版本中的起始位置坐标为：159916733；结束位置坐标为：159989205。正确的基因信息定位是基因检测和对检测结果进行正确解读的关键。

佳学基因解码对该基因的功能分类：国际版

G-protein coupled receptors/GPCRs excl olfactory receptors

基因解码对该基因的功能分类：中文版

G 蛋白偶联受体/GPCR 不包括嗅觉受体

结构与功能基因解码所揭示的该基因在细胞内发挥作用的场所（国际版）：

Plasma membrane(Supported)

结构与功能基因解码所揭示的该基因发挥作用的细胞内位置（中文版）：

质膜

该基因序列变化后增加的疾病风险（国际版）：

Neurotoxicity Syndromes; Hypotension; Cardiomegaly; Kidney Diseases; Nerve Degeneration; Mood Disorders; Seizures; Liver Cirrhosis, Experimental

如果该基因突变后，风险可能增加的疾病类型（中文版）：

神经毒性综合征；低血压;心脏肥大；肾脏疾病；神经退化；情绪障碍；癫痫发作；肝硬化实验性

GWAS基因检测所建立的与该基因的疾病关联（国际版）：

正在通过基因解码技术进行收集、查证并编辑，请关注佳学基因，获得及明更新的人类基因序列变化与疾病表征数据库的更新内容

GWAS基因检测所解码的该基因突变会增加风险的疾病种类（中文版）：

正在通过基因解码技术进行收集、查证并编辑，请关注佳学基因，获得及明更新的人类基因序列变化与疾病表征数据库的更新内容

以该基因做靶点的药物（国际版）：

Midodrine (Protein heterodimerization activity);Ziprasidone (Protein heterodimerization activity);Cabergoline (Protein heterodimerization activity);Dapiprazole (Protein heterodimerization activity);Amitriptyline (Protein heterodimerization activity);Olanzapine (Protein heterodimerization activity);Alfuzosin (Protein heterodimerization activity);Clozapine (Protein heterodimerization activity);Norepinephrine (Protein heterodimerization activity);Phenylephrine (Protein heterodimerization activity);Loxapine (Protein heterodimerization activity);Promazine (Protein heterodimerization activity);Prazosin (Protein heterodimerization activity);Imipramine (Protein heterodimerization activity);Chlorpromazine (Protein heterodimerization activity);Nortriptyline (Protein heterodimerization activity);Clonidine (Protein heterodimerization activity);Doxazosin (Protein heterodimerization activity);Nicardipine (Protein heterodimerization activity);Epinephrine (Protein heterodimerization activity);Thioridazine (Protein heterodimerization activity);Ergotamine (Protein heterodimerization activity);Tamsulosin (Protein heterodimerization activity);Methoxamine (Protein heterodimerization activity);Trimipramine (Protein heterodimerization activity);Risperidone (Protein heterodimerization activity);Modafinil (Protein heterodimerization activity);Propiomazine (Protein heterodimerization activity);Fenoldopam (Protein heterodimerization activity);Phenoxybenzamine (Protein heterodimerization activity);Oxymetazoline (Protein heterodimerization activity);Carvedilol (Protein heterodimerization activity);Doxepin (Protein heterodimerization activity);Nefazodone (Protein heterodimerization activity);Terazosin (Protein heterodimerization activity);Pergolide (Protein heterodimerization activity);Bromocriptine (Protein heterodimerization activity);Quetiapine (Protein heterodimerization activity);Aripiprazole (Protein heterodimerization activity);Lisdexamfetamine (Protein heterodimerization activity);Paliperidone (Protein heterodimerization activity);Methotrimeprazine (Protein heterodimerization activity);Dextroamphetamine (Protein heterodimerization activity);Phendimetrazine (Protein heterodimerization activity);Propericiazine (Protein heterodimerization activity);Acepromazine (Protein heterodimerization activity);Thioproperazine (Protein heterodimerization activity);Dronedarone (Protein heterodimerization activity);R450 (Protein heterodimerization activity);Epicept NP-1 (Protein heterodimerization activity);Sertindole (Protein heterodimerization activity);Silodosin (Protein heterodimerization activity);Droxidopa (Protein heterodimerization activity);Xylometazoline (Protein heterodimerization activity);Brexpiprazole (Protein heterodimerization activity);Cirazoline (Protein heterodimerization activity)

针对该基因所产生的突变，可能有正确效果的药物（中文版）：

米多君（蛋白质异二聚活性）；齐拉西酮（蛋白质异二聚活性）；卡麦角林（蛋白质异二聚活性）；达哌唑（蛋白质异二聚活性）；阿米替林（蛋白质异二聚活性）；奥氮平（蛋白质异二聚活性）；阿夫唑嗪（蛋白质异二聚活性）；氯氮平(蛋白质异二聚活性);去甲肾上腺素(蛋白质异二聚活性);去氧肾上腺素(蛋白质异二聚活性);洛沙平(蛋白质异二聚活性);丙嗪(蛋白质异二聚活性);哌唑嗪(蛋白质异二聚活性);丙咪嗪(蛋白质异二聚活性);氯丙嗪(蛋白质异二聚活性);去甲替林(蛋白质异二聚活性);可乐定(蛋白质异二聚活性);多沙唑嗪(蛋白质异二聚活性);尼卡地平(蛋白质异二聚活性);肾上腺素(蛋白质异二聚活性);硫利达嗪(蛋白质异二聚活性);麦角胺(蛋白质异二聚活性)异二聚活性);坦索罗辛(蛋白质异二聚活性);甲氧明(蛋白质异二聚活性);曲米帕明(蛋白质异二聚活性);利培酮(蛋白质异二聚活性);莫达非尼(蛋白质异二聚活性);丙哌嗪(蛋白质异二聚活性);非诺多泮(蛋白质异二聚活性)活性);苯氧苄胺(蛋白质异二聚活性);羟甲唑啉(蛋白质异二聚活性);卡维地洛(蛋白质异二聚活性);多塞平(蛋白质异二聚活性);奈法唑酮(蛋白质异二聚活性);特拉唑嗪(蛋白质异二聚活性);培高利特(蛋白质异二聚活性) );溴隐亭(蛋白质异二聚活性);喹硫平(蛋白质异二聚活性);阿立哌唑(蛋白质异二聚活性);Lisdexamfetamine(蛋白质异二聚活性);帕潘立酮(蛋白质异二聚活性);甲氧美拉嗪(蛋白质异二聚活性);右苯丙胺(蛋白质异二聚活性) ;苯二甲曲嗪（蛋白质异二聚活性）;丙哌嗪（蛋白质异二聚活性）;乙酰丙嗪（蛋白质异二聚活性）;硫丙哌嗪（蛋白质异二聚活性）;决奈达隆（蛋白质异二聚活性）;R450（蛋白质异二聚活性）;Epicept NP-1（蛋白质异二聚活性）活性);舍吲哚(蛋白质异二聚活性);西洛多辛(蛋白质异二聚活性);屈昔多巴(蛋白质异二聚活性);赛洛唑啉(蛋白质异二聚活性);Brexpiprazole(蛋白质异二聚活性);西拉唑啉(蛋白质异二聚活性)